NCT04826393 - ASP8374 + Cemiplimab in Recurrent Glioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

October 31, 2022

Study Completion Date

January 1, 2024

Conditions

GlioblastomaRecurrent Glioblastoma

Interventions

DRUG

ASP8374

every 3 weeks by intravenous infusion

DRUG

cemiplimab

intravenous infusion

Trial Locations (4)

Columbia University Medical Center, New York

Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia

University of Cincinnati Medical Center, Cincinnati

Brigham and Women's Hospital, Boston